<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="212">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01192763</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000683470</org_study_id>
    <secondary_id>UCCRC-10-089-A</secondary_id>
    <nct_id>NCT01192763</nct_id>
  </id_info>
  <brief_title>RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer</brief_title>
  <official_title>.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>Unspecified</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for
      cell growth. Giving RO4929097 before surgery may make the tumor smaller and reduce the
      amount of normal tissue that needs to be removed.

      PURPOSE: This phase I trial is studying the side effects of RO4929097 before surgery in
      treating patients with pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the effects of neoadjuvant gamma-secretase inhibitor RO4929097 on Notch
           inhibition via interrogation of Hes-1 expression in patients with pancreatic cancer.

      Secondary

        -  To evaluate the effects of this regimen on pancreatic cancer stem cell self-renewal and
           tumorigenesis as compared to pancreatic stem cells from controls (patients who do not
           receive treatment).

        -  To evaluate the safety of this regimen in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-11 in the
      absence of disease progression or unacceptable toxicity. Beginning 7 days after completion
      of gamma-secretase inhibitor RO4929097, patients undergo complete resection comprising
      pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy based on the
      anatomic location of the cancer.

      Tumor tissue from biopsy and surgery and blood samples are collected for pharmacodynamic
      studies.

      After completion of study therapy, patients are followed up every 3 months for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Notch activity (expression of Hes-1)</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of cancer stem cells (CD44+, CD24+, ESA+ population of cells) self-renewal and tumorigenesis as measured by FACS</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gamma-secretase/Notch signalling pathway inhibitor RO4929097</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed pancreatic adenocarcinoma

               -  T1-3, N0-1, and M0 disease

          -  Surgically resectable disease confirmed by a surgeon experienced in pancreatic
             surgery

               -  No borderline resectable disease defined as any of the following:

                    -  Tumors with severe unilateral or bilateral SMV/portal involvement
                       impingement

                    -  Abutment (or) encasement of hepatic artery

                    -  SMA or celiac encasement (or) presence of SMV occlusion by tumor

          -  No metastatic disease

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Life expectancy &gt; 6 months

          -  WBC ≥ 3,000/mm³

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 9 g/dL

          -  Total bilirubin normal

          -  AST and ALT ≤ 2.5 times upper limit of normal

          -  Creatinine &lt; 2.0 mg/dL

          -  Calcium, magnesium, phosphorous, and potassium normal

          -  Negative pregnancy test

          -  Not pregnant or nursing

          -  Fertile patients must use effective barrier-method contraception 4 weeks before,
             during, and for ≥ 12 months after completion of treatment

          -  Able to swallow tablets

          -  No malabsorption syndrome or other condition that would interfere with intestinal
             absorption

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to gamma-secretase inhibitor RO4929097 or other agents used in
             the study

          -  No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or
             hypokalemia despite adequate electrolyte supplementation

          -  No uncontrolled intercurrent illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia other than chronic

               -  Stable atrial fibrillation

               -  Psychiatric illness/social situations that would limit compliance with study
                  requirements

          -  No baseline QTcF &gt; 450 msec (male) or QTcF &gt; 470 msec (female)

          -  No other cancer within the past 5 years except carcinoma in situ of the uterine
             cervix or adequately treated basal cell carcinoma of the skin

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered to &lt; grade 2 toxicity related to prior therapy

          -  No prior chemotherapy or radiotherapy for pancreatic cancer

          -  No other concurrent investigational agents

          -  No concurrent medications with narrow therapeutic indices that are metabolized by
             cytochrome P450 (CYP450), including warfarin sodium (Coumadin®), ketoconazole, or
             grapefruit juice

          -  No concurrent strong inducers or inhibitors of CYP3A4

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent anticancer agents or therapies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gazala Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tower Cancer Research Foundation</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solomon I. Hamburg, MD, PhD</last_name>
      <phone>310-888-8680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - City of Hope Comprehensive Cancer Cen</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089-9181</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - USC/Norris Comprehensive Cancer Cente</last_name>
      <phone>323-865-0451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark V. McNamara, MD</last_name>
      <phone>626-396-2900</phone>
      <email>mmcnamara@ccsmg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - University of California Davis Cancer</last_name>
      <phone>916-734-3089</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - University of Chicago Cancer Research</last_name>
      <phone>773-834-7424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital Cancer Care Institute</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Decatur Memorial Hospital Cancer Care</last_name>
      <phone>217-876-4750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201-1781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Evanston Hospital</last_name>
      <phone>847-570-1381</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ingalls Cancer Care Center at Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Ingalls Cancer Care Center at Ingalls</last_name>
      <phone>708-915-4673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center at Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cardinal Bernardin Cancer Center</last_name>
      <phone>708-226-4357</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of Central Illinois, PC - Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615-7828</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sachdev P. Thomas, MD</last_name>
      <phone>309-243-1000</phone>
      <email>sthomas@ohaci.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Illinois Hematology Oncology Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edem S. Agamah, MD, MS</last_name>
      <phone>217-525-2500</phone>
      <email>ihdn@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46885-5099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sreenivasa R. Nattam, MD</last_name>
      <phone>260-484-8830</phone>
      <email>ledgar@fwmoh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Greenebaum Cancer Center at Universit</last_name>
      <phone>800-888-8823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - University of Michigan Comprehensive</last_name>
      <phone>800-865-1125</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>David C. Pratt Cancer Center at St. John's Mercy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - David C. Pratt Cancer Center at St. J</last_name>
      <phone>314-251-6770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Penn State Hershey Cancer Institute a</last_name>
      <phone>717-531-3779</phone>
      <email>CTO@hmc.psu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - UPMC  Cancer Centers</last_name>
      <phone>412-647-8073</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Medical College of Wisconsin Cancer C</last_name>
      <phone>414-805-4380</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials/UCCRC-10-089-A</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>February 24, 2011</lastchanged_date>
  <firstreceived_date>August 31, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Gazala Khan</name_title>
    <organization>University of Michigan Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>stage IA pancreatic cancer</keyword>
  <keyword>stage IB pancreatic cancer</keyword>
  <keyword>stage IIA pancreatic cancer</keyword>
  <keyword>stage IIB pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
</clinical_study>
